AgomAb Therapeutics NV (AGMB)
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States.
$12.58-0.01%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago-14.1%
The outlook
AgomAb Therapeutics NV currently reads as leaning bullish based on strong buy — 1.4 avg of 5 analysts, above its 50- & 200-day averages, 42% of the way from its 52-week low to high, avg target +162% vs current price. This is a snapshot of current market data, not a forecast.
What’s behind the score
Analyst consensusStrong Buy — 1.4 avg of 5 analysts
Price trendAbove its 50- & 200-day averages
52-week range42% of the way from its 52-week low to high
Price targetAvg target +162% vs current price
Analyst price target
~12-month · 5 analysts$33.00average target+162.3% vs now
Now $12.58
Low $28.00High $36.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$619.5M
52-wk high
$17.82
52-wk low
$8.75
50-day avg
$11.88
200-day avg
$12.37
Trailing P/E
—